Geneos Wealth Management Inc. Halozyme Therapeutics, Inc. Transaction History

Geneos Wealth Management Inc.

$2.6 Billion
Q3 2024

A detailed history of Geneos Wealth Management Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Geneos Wealth Management Inc. holds 4,050 shares of HALO stock, worth $213,840. This represents 0.01% of its overall portfolio holdings.

Number of Shares

4,050

Previous 4,550 10.99%

Holding current value

$213,840

Previous $238,000 2.94%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$51.3 - $64.42 $25,650 - $32,210	-500 Reduced 10.99%	4,050 $231,000
Q2 2024 Jul 23, 2024	BUY	$37.81 - $52.4 $7,562 - $10,480	200 Added 4.6%	4,550 $238,000
Q1 2023 Apr 25, 2023	SELL	$32.86 - $55.7 $6,572 - $11,140	-200 Reduced 4.4%	4,350 $166,000
Q4 2022 Jan 30, 2023	BUY	$40.06 - $59.44 $24,036 - $35,664	600 Added 15.19%	4,550 $258,000
Q3 2022 Nov 14, 2022	SELL	$38.53 - $51.78 $383,373 - $515,211	-9,950 Reduced 71.58%	3,950 $156,000
Q2 2022 Jul 22, 2022	SELL	$37.35 - $48.3 $14,940 - $19,320	-400 Reduced 2.8%	13,900 $611,000
Q1 2022 May 16, 2022	SELL	$31.97 - $41.06 $6,394 - $8,212	-200 Reduced 1.38%	14,300 $570,000
Q4 2021 Feb 09, 2022	SELL	$31.82 - $40.75 $12,728 - $16,300	-400 Reduced 2.68%	14,500 $583,000
Q3 2021 Nov 09, 2021	SELL	$38.47 - $46.42 $9,617 - $11,605	-250 Reduced 1.65%	14,900 $607,000
Q2 2021 Jul 08, 2021	SELL	$38.84 - $51.31 $41,170 - $54,388	-1,060 Reduced 6.54%	15,150 $703,000
Q1 2021 Jun 17, 2021	BUY	$39.51 - $51.45 $395 - $514	10 Added 0.06%	16,210 $809,000
Q4 2020 May 19, 2021	SELL	$25.81 - $43.62 $117,435 - $198,471	-4,550 Reduced 21.93%	16,200 $670,000
Q3 2020 Sep 07, 2021	SELL	$25.74 - $29.63 $57,915 - $66,667	-2,250 Reduced 9.78%	20,750 $540,000
Q2 2020 Sep 07, 2021	SELL	$16.25 - $26.81 $8,125 - $13,405	-500 Reduced 2.13%	23,000 $569,000
Q1 2020 Sep 07, 2021	SELL	$13.9 - $21.83 $12,510 - $19,647	-900 Reduced 3.69%	23,500 $411,000
Q4 2019 Sep 07, 2021	SELL	$14.93 - $19.53 $20,902 - $27,342	-1,400 Reduced 5.43%	24,400 $438,000
Q3 2019 Sep 07, 2021	SELL	$15.2 - $17.69 $7,600 - $8,845	-500 Reduced 1.9%	25,800 $392,000
Q2 2019 Sep 07, 2021	SELL	$14.75 - $17.26 $8,850 - $10,356	-600 Reduced 2.23%	26,300 $451,000
Q1 2019 Sep 07, 2021	SELL	$13.94 - $17.58 $13,940 - $17,580	-1,000 Reduced 3.58%	26,900 $433,000
Q2 2018 Sep 07, 2021	SELL	$16.87 - $20.3 $5,061 - $6,090	-300 Reduced 1.06%	27,900 $470,000
Q1 2018 Sep 07, 2021	SELL	$17.06 - $21.2 $5,118 - $6,360	-300 Reduced 1.05%	28,200 $552,000
Q4 2017 Sep 07, 2021	SELL	$16.75 - $20.8 $5,025 - $6,240	-300 Reduced 1.04%	28,500 $577,000
Q2 2017 Sep 07, 2021	SELL	N/A	-1,500 Reduced 4.95%	28,800 $369,000
Q1 2017 Sep 07, 2021	BUY	N/A	800 Added 2.71%	30,300 $392,000
Q4 2016 Sep 07, 2021	BUY	N/A	1,800 Added 6.5%	29,500 $291,000
Q3 2016 Sep 07, 2021	BUY	N/A	200 Added 0.73%	27,700 $334,000
Q2 2016 Sep 07, 2021	BUY	N/A	700 Added 2.61%	27,500 $251,000
Q1 2016 Sep 07, 2021	BUY	N/A	26,800	26,800 $261,000

Others Institutions Holding HALO

# of Institutions

542

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.35B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geneos Wealth Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Geneos Wealth Management Inc. with notifications on news.

Account

Geneos Wealth Management Inc. Halozyme Therapeutics, Inc. Transaction History